Lilly commits $3 billion to China ahead of an obesity pill filing there

Eli Lilly said on March 11 that it will invest $3 billion in China over the next decade, largely to expand manufacturing capacity ahead of a possible approval for orforglipron, its once-daily oral GLP-1 pill for obesity and type 2 diabetes ^[1][2]. The company submitted a marketing application for the drug to China's National Medical Products Administration at the end of 2025 ^[1].

The investment will build a "localized production and supply system for oral solid dosage forms," centered on Lilly's existing plant in Suzhou, along with a network of outside manufacturing partners ^[2]. As part of the plan, Lilly signed a $200 million deal with contract manufacturer Pharmaron to allow it to expand production "as needed" ^[2]. Lilly said it has already spent $200 million on the Suzhou plant in the past two years and has invested $6 billion in China overall, covering research, an innovation center, and a biotech incubator ^[2].

Orforglipron is not yet approved anywhere. In a late-stage trial, it helped overweight adults without diabetes lose 12.4% of their body weight over 72 weeks at the highest dose ^[1]. A separate study found it helped maintain weight loss in patients who switched to it from injectable GLP-1 drugs, including Lilly's own Zepbound (tirzepatide) and Novo Nordisk's Wegovy (semaglutide) ^[1].

China is a market where domestic drugmakers already sell incretin-based treatments at low prices, and the country has an estimated obesity rate of nearly 9% ^[2]. Lilly is not alone in expanding there: AstraZeneca recently announced a $15 billion China manufacturing investment, and Haleon has made similar moves ^[1][2]. Not every company is going the same direction, though. Bristol Myers Squibb said in September 2025 that it agreed to sell its 60% stake in a Chinese pharmaceutical joint venture, which included a Shanghai manufacturing facility ^[1]. Lilly's announcement also came ahead of a planned summit between President Trump and China's Xi Jinping ^[1], and it follows pressure from the Trump administration for drugmakers to build more manufacturing inside the United States, a push that led Lilly to add $27 billion to its U.S. investment target for a total of $50 billion ^[2].

Why it matters for patients

This announcement is about supply chains and regulatory strategy in China, not about US access, pricing, or approval timelines for orforglipron. Nothing in the sources says this investment changes when or how the pill might reach US pharmacies, since Lilly is pursuing separate US regulatory review for orforglipron. For US patients or those researching options, the practical relevance is limited: the news mainly signals that Lilly sees a large potential market in China and is racing to compete against domestic incretin drugs that are already sold there at lower prices ^[2]. It also shows that Lilly is building manufacturing capacity for orforglipron on two fronts at once, in China and in the US, which could matter for supply if the drug is eventually approved in multiple markets. Whether Chinese approval or manufacturing scale-up has any effect on US pricing or availability is not addressed in these sources and is not yet known.

What happens next

Orforglipron's marketing application is currently under review by China's National Medical Products Administration, following submission at the end of 2025 ^[1]. No timeline for a Chinese approval decision is given in the sources. The $3 billion investment is described as unfolding over the next decade, with the Suzhou facility and the Pharmaron partnership as initial steps ^[2]. Separately, a summit between President Trump and Xi Jinping was expected this March, though the sources do not say whether pharmaceutical trade or investment was on the agenda ^[1]. US regulatory status for orforglipron is not detailed in these sources.